$349 Million is the total value of GREAT POINT PARTNERS LLC's 39 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| DERM | New | DERMIRA INC | $23,400,000 | – | 800,000 | +100.0% | 6.70% | – |
| EGRX | New | EAGLE PHARMACEUTICALS INC | $21,268,000 | – | 548,290 | +100.0% | 6.09% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $11,863,000 | – | 538,024 | +100.0% | 3.40% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $9,943,000 | – | 330,000 | +100.0% | 2.85% | – |
| ITCI | New | INTRA CELLULAR THERAPIES INC | $3,882,000 | – | 100,000 | +100.0% | 1.11% | – |
| MCRB | New | SERES THERAPEUTICS INCput | $3,486,000 | – | 120,000 | +100.0% | 1.00% | – |
| FOMX | New | FOAMIX PHARMACEUTICALS LTD | $1,745,000 | – | 274,756 | +100.0% | 0.50% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $1,738,000 | – | 550,116 | +100.0% | 0.50% | – |
| ASND | New | ASCENDIS PHARMA A Ssponsored adr | $1,015,000 | – | 76,511 | +100.0% | 0.29% | – |
| DPRX | New | DIPEXIUM PHARMACEUTICALS INC | $871,000 | – | 87,914 | +100.0% | 0.25% | – |
| AXGT | New | AXOVANT SCIENCES LTD | $321,000 | – | 25,000 | +100.0% | 0.09% | – |
| RVNC | New | REVANCE THERAPEUTICS INC | $295,000 | – | 21,665 | +100.0% | 0.08% | – |
| ARDX | New | ARDELYX INC | $30,000 | – | 3,444 | +100.0% | 0.01% | – |
| AMRN | New | AMARIN CORP PLCspon adr new | $4,000 | – | 2,000 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-06-05 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.